This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Bionomics Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Spyros Papapetropoulos
Chief executive officer
n/a
Total compensation
CEO salary percentage
n/a
CEO tenure
less than a year
CEO ownership
n/a
Management average tenure
less than a year
Board average tenure
3yrs
Recent management updates
Recent updates
CEO
Spyros Papapetropoulos (50 yo)
less than a year
Tenure
Dr. Spyridon Papapetropoulos, M. D., Ph. D., also known as Spyros, serves as Director, President & Chief Executive Officer at Bionomics Limited from January 05, 2023. He serves as Member of Scientific Advi...
Leadership Team
Name
Position
Tenure
Compensation
Ownership
Adrian Hinton
Financial Controller
less than a year
AU$323.78k
0.0048% € 305.4
Spyridon Papapetropoulos
CEO, President & Director
less than a year
no data
no data
Timothy Cunningham
Chief Financial Officer
less than a year
no data
no data
Paul Rolan
Consultant Chief Medical Officer of Clinical Neuroscience
no data
AU$102.00k
no data
Julie Kerner
Senior Vice President of Business Operations
less than a year
no data
no data
Atul Mahableshwarkar
Acting Chief Medical Officer
less than a year
no data
no data
Suzanne Irwin
Company Secretary
2.4yrs
no data
no data
0.3yrs
Average Tenure
60yo
Average Age
Experienced Management: B1N's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.
Board Members
Name
Position
Tenure
Compensation
Ownership
Spyridon Papapetropoulos
CEO, President & Director
less than a year
no data
no data
Errol B. De Souza
Non-Executive Director
15.6yrs
AU$4.03m
0.025% € 1.6k
David Wilson
Independent Non-Executive Director
7.3yrs
AU$87.00k
0.017% € 1.1k
Alan Fisher
Independent Non-Executive Chair of the Board
7yrs
AU$87.00k
0.0068% € 436.1
Jane Ryan
Independent Non-Executive Director
2.9yrs
AU$93.15k
0% € 0
Srinivas Rao
Member of Clinical Advisory Board
1.9yrs
AU$57.75k
no data
Murray Stein
Member of Clinical Advisory Board
no data
no data
no data
Steven Williams
Scientific Advisor
no data
no data
no data
Allan Young
Scientific Advisor
no data
no data
no data
Marina Picciotto
Scientific Advisor
no data
no data
no data
Peter Miles Davies
Independent Non-Executive Director
2.2yrs
AU$77.00k
0.018% € 1.2k
Aaron N. Weaver
Independent Non-Executive Nominee Director
3.2yrs
AU$77.00k
no data
3.0yrs
Average Tenure
56.5yo
Average Age
Experienced Board: B1N's board of directors are considered experienced (3 years average tenure).
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2023/09/01 17:10
End of Day Share Price
2023/08/24 00:00
Earnings
2022/12/31
Annual Earnings
2022/06/30
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Neuphoria Therapeutics Inc. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.